Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis
暂无分享,去创建一个
J. Kutok | H. Kantarjian | J. Cortes | S. Verstovsek | F. Ravandi | R. Mesa | J. Gotlib | K. Newberry | K. Sasaki | P. Kelly
[1] Hongwei Wang,et al. Epidemiology of myeloproliferative neoplasms in the United States , 2014, Leukemia & lymphoma.
[2] T. Barbui,et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. , 2013, Blood.
[3] J. Dipersio,et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I , 2013, Haematologica.
[4] J. Dipersio,et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I , 2013, Haematologica.
[5] E. Stanchina,et al. Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis , 2013 .
[6] D. McCoy,et al. Platelet-derived growth factor-A and sonic hedgehog signaling direct lung fibroblast precursors during alveolar septal formation. , 2013, American journal of physiology. Lung cellular and molecular physiology.
[7] R. Badolato,et al. The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse. , 2013, Blood.
[8] C. Rudin,et al. Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors , 2013, Clinical Cancer Research.
[9] M. Cazzola,et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. , 2012, Blood.
[10] Jason Gotlib,et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.
[11] Francisco Cervantes,et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.
[12] M. Baccarani,et al. Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies , 2011 .
[13] T. Barbui,et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. , 2011, Blood.
[14] M. Griesshammer,et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Tallman,et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. , 2010, Blood.
[16] M. Scott,et al. The output of Hedgehog signaling is controlled by the dynamic association between Suppressor of Fused and the Gli proteins. , 2010, Genes & development.
[17] H. Kantarjian,et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] David Allard,et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.
[19] R. Mesa,et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.
[20] P. Fenaux,et al. Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms , 2008, Leukemia.
[21] L. Greenbaum. Hedgehog signaling in biliary fibrosis. , 2008, The Journal of clinical investigation.
[22] N. Shinton. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .
[23] Francisco Cervantes,et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). , 2007, Leukemia research.
[24] H. Deeg,et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). , 2006, Blood.
[25] R. Mesa,et al. Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosiswith myeloid metaplasia at the Mayo Clinic , 2006, Cancer.
[26] H. Kantarjian,et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia , 2006, Cancer.
[27] Marina Pasca di Magliano,et al. Hedgehog signalling in cancer formation and maintenance , 2003, Nature Reviews Cancer.
[28] Jussi Taipale,et al. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. , 2002, Genes & development.
[29] P. Sánchez,et al. Gli and hedgehog in cancer: tumours, embryos and stem cells , 2002, Nature Reviews Cancer.
[30] P. Mouton,et al. Length measurement: new developments in neurostereology and 3D imagery , 2000, Journal of Chemical Neuroanatomy.
[31] M. Scott,et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine , 2000, Nature.
[32] A. Tefferi. Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.
[33] T. Taguchi,et al. [Phase I study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.
[34] A. Manoharan,et al. MANAGEMENT OF MYELOFIBROSIS WITH INTERMITTENT HYDROXYUREA , 1991, British journal of haematology.
[35] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[36] O. M. Ávila-Cabrera,et al. BCR-ABL negative myeloproliferative neoplasms , 2013 .
[37] J. D. van der Walt,et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.